DNA Vaccine Market Expected to Reach $0.77 Billion by 2030 | CAGR of 6.3%

According to a new report published by Allied Market Research, titled, “DNA Vaccines Market by Product Type, Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global DNA vaccine market size was valued at $0.42 Billion in 2020 and is projected to reach $0.77 Billion by 2030 registering a CAGR of 6.3% from 2021 to 2030.

A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response. DNA vaccines work by injecting genetically engineered plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, so the cells directly produce the antigen, thus causing a protective immunological response.

Growth in prevalence of cancer and infectious diseases in human and animals, and rise in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature are principle driving factors, which boost growth of the DNA vaccine market. In addition, increase in number of antibiotics resistant pathogens, further boost the DNA vaccine market. However, lack of immunogenicity associated with DNA vaccines is one of the restraining factors, which may hinder growth of the market. In addition, limited knowledge of the effects of DNA vaccines on humans also hamper growth of the market. On the contrary, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies creates an opportunity for the manufacturers to tap and capitalize on the market.

COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The COVID-19 pandemic has restraint the industry growth significantly, as the pandemic has greatly affected veterinary revenue of hospitals and clinics, owing to decline in number of visits amid nationwide lockdowns along with changing animal healthcare approach for providing care to emergency cases and critically ill animals. Thus, the outbreak of COVID-19 has negatively impacted the DNA vaccine market.

The DNA vaccine market is segmented on the basis of product type, type, end user, and region. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. The Oncept was the major shareholder 2020, owing to increase in prevalence of canine melanoma cancer in animals, especially in dogs, which also increases demand for Oncept vaccine.

By type, the market is segmented into therapeutic vaccine, and prophylactic vaccines. The prophylactic vaccines segment dominated the global DNA vaccines market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to the availability of prophylactic vaccines for the treatment of animal diseases such as West Nile virus, and Hematopoietic Necrosis virus.

Based on end user, it is categorized into veterinary clinics and veterinary hospitals. The veterinary hospitals segment acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the rise in incidences of animal diseases, increase in hospital admissions of animals for vaccine dose, and availability of trained veterinarian in the hospitals.

Key Findings of the Study

• Based on product type, the Oncept segment held the largest share in the global DNA vaccine market in 2020.
• Based on type, the prophylactic vaccines segment held the largest market share in 2020 and is expected to remain dominant throughout the forecast period.
• Based on end user, the veterinary hospitals segment dominated the global DNA vaccine market in 2020 and is expected to remain dominant throughout the forecast period.   

U.S. was the largest revenue contributor in North America in 2020, and is a mature market owing to factors such as DNA vaccine product approval in the country, presence of major key players, and presence of well-established healthcare infrastructure, higher buying power, and higher healthcare expenditure levels.